A new analysis of more than 30 million FDA adverse event reports has found that Wegovy — the higher-dose version of semaglutide used specifically for weight loss — carries a meaningfully stronger safety signal for a rare eye condition than other semaglutide formulations, including Ozempic.
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It is sometimes described as an "eye stroke." It occurs when blood flow to the optic nerve is reduced or blocked, damaging the nerve that carries visual signals from the eye to the brain. The condition can cause sudden, often permanent, loss of vision in one eye — typically with no warning and no surgical reversal.
The study, published March 10, 2026, in the British Journal of Ophthalmology, analyzed voluntary adverse event reports submitted to the FDA's Adverse Event Reporting System between December 2017 and December 2024. The researchers focused specifically on reports involving the three semaglutide products: Ozempic, Wegovy, and Rybelsus. They found a safety signal — a pattern suggesting a possible drug-event association — for all three, but the signal was nearly five times stronger for Wegovy than for Ozempic, despite both medications containing the same active ingredient, semaglutide.
The studies do not prove that Wegovy causes NAION. The FDA's adverse event database reflects voluntary reports, which can be influenced by media attention, prescribing patterns, and other factors. What the researchers have identified is a safety signal — a pattern that warrants closer study, not a confirmed causal relationship.
Why This Matters
Wegovy is currently one of the most prescribed medications in the United States. An estimated 15 to 20 million Americans are using GLP-1 receptor agonists of some kind, with Wegovy specifically — the highest-dose semaglutide formulation — prescribed to patients seeking weight management. Novo Nordisk has reported millions of active Wegovy prescriptions in the United States alone.
The concern raised by this analysis is not that NAION is common. It is rare. What makes it clinically significant is that the vision loss it causes is often sudden, typically permanent, and currently has no effective surgical or medical reversal. Patients who develop NAION may lose a significant portion of their visual field in one eye overnight.
The finding that the signal is stronger for Wegovy than for Ozempic — despite sharing the same active molecule — is what researchers describe as dose-dependent. Wegovy is approved at a maximum dose of 2.4 mg weekly, compared to Ozempic's maximum approved dose of 2 mg weekly. That difference in dosage may translate to a more pronounced vascular effect on the optic nerve at high doses — though that mechanism has not been definitively confirmed.
For the millions of Americans currently taking Wegovy, this research is a reason to have a conversation with their prescribing physician — not a reason to stop their medication without medical guidance.
What We Know So Far
The British Journal of Ophthalmology analysis examined reports from the FDA Adverse Event Reporting System (FAERS) database covering December 2017 through December 2024 — a dataset of more than 30 million adverse event reports. The researchers looked specifically at reports where a GLP-1 receptor agonist was identified as a suspected cause in cases of ischemic optic neuropathy.
Key findings from the analysis:
- All three semaglutide formulations — Ozempic, Wegovy, and Rybelsus — showed a safety signal for ischemic optic neuropathy
- The signal was absent for comparator drugs used in the same patient population
- The signal was nearly five times stronger for Wegovy than for Ozempic
- The signal was more pronounced in men than in women
- Researchers suggested that dose, formulation, treatment population, low blood pressure, or fluid loss could help explain the difference between Wegovy and Ozempic
- Media attention may have contributed to higher Wegovy reporting rates, which the authors explicitly acknowledged as a limitation
A companion commentary published in the same journal stated that these findings add to an emerging body of literature reporting ocular complications with anti-obesity medications, which warrants further scrutiny and urgent clarification.
Where the Risk May Be Concentrated
NAION is more common in people with specific underlying risk factors, and researchers believe those factors may interact with the effects of high-dose semaglutide.
Individuals at higher baseline risk for NAION include those with a small optic disc (a structural feature sometimes called a "disc at risk"), high blood pressure, diabetes, obstructive sleep apnea, and a history of cardiovascular disease. These are the same conditions that commonly co-occur in patients prescribed Wegovy for obesity.
The analysis found the signal was particularly pronounced in men. Researchers suggested that the combination of Wegovy's high dose, potential blood pressure lowering at night, and fluid loss — all known effects of the drug — could make the optic nerve more vulnerable to ischemic injury in predisposed individuals.
What Doctors and Experts Say
Dr. Hector Perez, MD, a board-certified bariatric surgeon at Renew Bariatrics and an advisor at BestSurgeons.com, who was not involved in the study, told Healthline that while the risk for ischemic optic neuropathy is worth monitoring, the study is very small in terms of the absolute numbers involved. He noted that the FAERS database cannot prove causation and that the reporting rates do not reflect actual incidence rates among all Wegovy users.
The authors of the British Journal of Ophthalmology study concluded that their findings provide the first evidence of a formulation- and dose-dependent ischemic optic neuropathy risk with the strongest association observed for Wegovy. They called for urgent prospective evaluation to guide prescribing and regulatory policy.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS)
- Data period: December 2017 to December 2024
- Published in: British Journal of Ophthalmology, March 10, 2026
- What it found: A safety signal for ischemic optic neuropathy with all three semaglutide formulations; the signal was nearly five times stronger for Wegovy than for Ozempic and was more pronounced in men
- What it did not prove: A causal relationship between Wegovy and NAION; FAERS-based analyses cannot determine true incidence rates or rule out confounding by media reporting bias, indication bias, or underlying risk factors
- What the FDA has done: As of the date of this article, the FDA has not issued a label change, drug safety communication, or recall related to this finding. Readers should monitor the FDA's MedWatch safety communications page for updates.
- What readers should know: Do not stop taking Wegovy without speaking to a prescribing physician. Report any sudden vision changes immediately and seek emergency ophthalmological evaluation.
Who Faces the Greatest Risk?
Based on what is currently known, the patients who may face elevated risk include:
- People taking Wegovy at the maximum 2.4 mg weekly dose
- Men (based on the sex-specific pattern observed in the analysis)
- People with a history of NAION in one eye, who face a risk of recurrence in the other eye
- People with obstructive sleep apnea, which causes repeated episodes of low oxygen and low blood pressure during sleep — a combination that may increase optic nerve vulnerability
- People with high blood pressure, cardiovascular disease, or diabetes
- People with the structural optic disc feature sometimes called a "disc at risk," which an ophthalmologist can identify
- People who are experiencing significant rapid weight loss with fluid loss while on Wegovy
Symptoms and Warning Signs to Watch For
NAION typically presents suddenly, often noticed upon waking. There is currently no reliably effective treatment once the damage has occurred, which makes early recognition critical.
Warning signs that require immediate emergency evaluation — call 911 or go to an emergency room:
- Sudden blurring of vision in one eye
- Sudden loss of vision in part of one eye, often described as a dark area or shadow
- Vision changes that appear to have occurred overnight or upon waking
- Any sudden change in vision not explained by a known condition
Do not dismiss sudden vision changes as eye fatigue. Any sudden unilateral vision change — in one eye only — in a patient taking Wegovy should be evaluated urgently by an ophthalmologist. NAION does not cause pain in most cases, which means patients may not initially feel that it is an emergency. It is.
What You Can Do Now
- If you are taking Wegovy, do not stop without speaking to your prescribing physician. The cardiovascular and metabolic benefits of semaglutide are real and well-established. Stopping abruptly may not be appropriate for your situation.
- Tell your prescribing physician about any history of NAION, vision problems, obstructive sleep apnea, or relevant cardiovascular risk factors.
- Consider asking for a baseline ophthalmology evaluation, particularly if you have risk factors for optic nerve ischemia.
- Report any sudden vision changes immediately to your doctor and seek emergency ophthalmological evaluation — do not wait for a scheduled appointment.
- Report adverse events to the FDA at fda.gov/safety/medwatch or by calling 1-800-FDA-1088.
- Monitor the FDA's drug safety communications page for any label changes or safety advisories related to semaglutide.
Cost and Access: What Patients Should Know
An ophthalmology evaluation for patients at risk or with visual symptoms typically costs between $100 and $300 without insurance, depending on location and the tests performed. Most insurance plans cover ophthalmology visits, and Medicare covers medically necessary eye exams.
For uninsured patients concerned about this risk, community health centers with vision services and Federally Qualified Health Centers can provide referrals. NAION evaluation requires a dilated fundus exam and, in some cases, optical coherence tomography (OCT) imaging — tests available at most ophthalmology practices.
If NAION is confirmed, there is currently no proven treatment that restores lost vision. Some clinical trials are evaluating neuroprotective agents. Patients with confirmed NAION should be monitored closely to reduce risk to the fellow eye.
What Happens Next
The researchers who conducted the British Journal of Ophthalmology analysis called explicitly for urgent prospective studies to determine whether Wegovy truly causes NAION, who is at greatest risk, and how to protect patients. Several academic medical centers are expected to launch prospective observational studies in 2026.
The FDA has not yet issued a formal safety communication or label update. The agency typically acts on FAERS signals after conducting its own review of the evidence. Readers should monitor the FDA's MedWatch page for any developments.
MedicalDaily will update this article if the FDA issues a safety communication or label change related to semaglutide and NAION.
The Bottom Line
A rigorous analysis of millions of FDA adverse event reports has identified a safety signal linking Wegovy to a rare but potentially devastating eye condition that can cause sudden, often permanent vision loss. The signal is stronger for Wegovy than for Ozempic, and stronger in men than in women. This does not prove that Wegovy causes NAION, and the absolute risk for any individual patient remains unknown. But for the millions of people now taking Wegovy, the message is clear: know the warning signs, share your medication history with any eye care provider, and seek immediate evaluation for any sudden vision change. Do not stop taking Wegovy without medical guidance — but do not dismiss vision symptoms as minor.
